Zevra Therapeutics (NASDAQ:ZVRA) Sets New 12-Month High - Time to Buy?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Friday . The company traded as high as $10.03 and last traded at $9.79, with a volume of 1176785 shares trading hands. The stock had previously closed at $9.41.

Wall Street Analyst Weigh In

ZVRA has been the topic of a number of recent research reports. HC Wainwright initiated coverage on shares of Zevra Therapeutics in a report on Wednesday. They issued a "buy" rating and a $26.00 target price on the stock. JMP Securities set a $18.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Guggenheim increased their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $23.14.

Zevra Therapeutics Price Performance

The stock's 50-day moving average is $8.63 and its 200-day moving average is $8.09. The company has a current ratio of 3.02, a quick ratio of 2.93 and a debt-to-equity ratio of 1.46.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The firm had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same quarter in the prior year, the company earned ($0.40) EPS. On average, analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Trading of Zevra Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ZVRA. Rhumbline Advisers increased its position in Zevra Therapeutics by 18.4% during the 4th quarter. Rhumbline Advisers now owns 68,053 shares of the company's stock worth $568,000 after purchasing an additional 10,573 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Zevra Therapeutics by 23.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 149,504 shares of the company's stock valued at $1,247,000 after acquiring an additional 28,148 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Zevra Therapeutics in the fourth quarter valued at approximately $224,000. Mystic Asset Management Inc. grew its position in Zevra Therapeutics by 1.9% in the fourth quarter. Mystic Asset Management Inc. now owns 313,347 shares of the company's stock valued at $2,613,000 after acquiring an additional 5,900 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. grew its position in Zevra Therapeutics by 3.1% in the fourth quarter. Retirement Planning Co of New England Inc. now owns 514,832 shares of the company's stock valued at $4,294,000 after acquiring an additional 15,327 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.